专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2006102684A3 ULTRA LOW STRENGTH ELECTRIC FIELD NETWORK-MEDIATED EX VIVO GENE, PROTEIN AND DRUG DELIVERY IN CELLS 审中-公开
公开(公告)号：WO2006102684A3
公开(公告)日：2006-09-28
申请号：PCT/US2006/011355
申请日：2006-03-16
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SEN, Luyi , GUANGGEN, Cui
发明人： SEN, Luyi , GUANGGEN, Cui
IPC分类号： A61K31/711 , C12N15/64
摘要： Ex vivo gene, protein or drug delivery to macroscopic quantities of various types of cells, cell clusters, or tissues using ultra low strength LSEFN strategies is disclosed in which the bioengineered cells and tissues are then systemically transfused, delivered or implanted into the various organs or tissue for the treatment of diseases. An LSEFN chamber is used which is shaped and sized to intimately contain the cells, cell clusters, or tissues in a transfusion chamber between opposing membrane encapsulated electrode arrays across which LSEFN pulses are applied.

82. 发明申请

WO2005077105A3 REDUCTION OF HIV-1 REPLICATION BY A MUTANT APOLIPOPROTEIN B MRNA EDITING ENZYME-CATALYTIC POLYPEPTIDE-LIKE 3 G (APOBEC3G) 审中-公开
标题翻译：减少艾滋病毒1复制由突变APOLIPOPROTEIN B MRNA编辑酶催化多肽样3 G（APOBEC3G）
公开(公告)号：WO2005077105A3
公开(公告)日：2006-09-21
申请号：PCT/US2005004483
申请日：2005-02-09
申请人： US GOV HEALTH & HUMAN SERV , PATHAK VINAY K , XU HONGZHAN , SVAROVSKAIA EVGUENIA S , BARR REBEKAH
发明人： PATHAK VINAY K , XU HONGZHAN , SVAROVSKAIA EVGUENIA S , BARR REBEKAH
IPC分类号： A61K38/43 , A01K67/02 , A61K31/711 , C07K14/775 , C12N5/00 , C12N9/00 , C12N15/63
CPC分类号： C07K14/775 , A61K38/00 , G01N33/502
摘要： Mutant APOBEC3G sequences are provided herein that reduce HIV-1 infection in the presence of HIV-Vif. In particular examples, mutant APOBEC3G molecules include (or encode for) a D128A, D128E, D128K, or D128V substitution. Methods of using the disclosed molecules for reducing HIV-1 infection are also provided, for example to treat a subject having an HIV-1 infection.
摘要翻译：本文提供了在HIV-Vif存在下减少HIV-1感染的突变型APOBEC3G序列。在具体实例中，突变体APOBEC3G分子包括（或编码）D128A，D128E，D128K或D128V取代。还提供了使用所公开的分子来降低HIV-1感染的方法，例如用于治疗具有HIV-1感染的受试者。

83. 发明申请

WO2006094917A2 FORMULATION WITH ANTI-TUMOR ACTION 审中-公开
标题翻译：具有抗肿瘤作用的配方
公开(公告)号：WO2006094917A2
公开(公告)日：2006-09-14
申请号：PCT/EP2006060306
申请日：2006-02-27
申请人： GENTIUM SPA , IACOBELLI MASSIMO , EISSNER GUENTHER , FERRO LAURA IRIS
发明人： IACOBELLI MASSIMO , EISSNER GUENTHER , FERRO LAURA IRIS
IPC分类号： A61K31/711 , A61P35/00
CPC分类号： A61K31/711
摘要： The use of oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically. The tumors which can be treated are preferably angiogenesis- dependent tumors, such as multiple myeloma or breast carcinoma.
摘要翻译：描述了使用分子量为4000-10000道尔顿的寡脱氧核糖核苷酸作为抗肿瘤剂，单独或与具有抗肿瘤作用的其它活性成分组合。寡肽可以通过从动物和/或植物组织，特别是来自哺乳动物器官的提取产生，或者可以合成制备。可以治疗的肿瘤优选是血管生成依赖性肿瘤，例如多发性骨髓瘤或乳腺癌。

84. 发明申请

WO2005115121A3 ADENYLYL CYCLASE ANTIBODIES, COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译： ADENYLYL CYCLASE抗体，组合物及其用途
公开(公告)号：WO2005115121A3
公开(公告)日：2006-07-20
申请号：PCT/US2005018589
申请日：2005-05-26
申请人： UNIV NEW JERSEY MED , VATNER STEPHEN F , VATNER DOROTHY E , SADOSHIMA JUNICHI , PAIN JAYASHREE
发明人： VATNER STEPHEN F , VATNER DOROTHY E , SADOSHIMA JUNICHI , PAIN JAYASHREE
IPC分类号： A61K39/44 , A61K31/7105 , A61K31/711 , A61K39/395 , C07K14/00 , C07K16/00 , C12N5/12
CPC分类号： G01N33/573 , A61K49/0008 , C07K16/40 , G01N2333/988 , G01N2800/32
摘要： The invention relates to compositions and methods for diagnosing and treating cardiac conditions and neurodegenerative diseases using antibodies which specifically recognize and bind to the adenylyl cyclase 5 isoform in the heart and brain. These antibodies demonstrate high specificity to the AC5 isoform and do not cross react to any other AC5 isoform. The invention further relates to methods of delivery of drugs to the site of injured tissue using the antibodies of the present invention.
摘要翻译：本发明涉及使用特异性识别和结合心脏和脑中的腺苷酸环化酶5同种型的抗体来诊断和治疗心脏病症和神经变性疾病的组合物和方法。这些抗体表现出对AC5同种型的高度特异性，并且不与任何其它AC5同种型交叉反应。本发明还涉及使用本发明的抗体将药物递送至损伤组织部位的方法。

85. 发明申请

WO2006032144A1 PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING FUCANS FROM VARIOUS ECHINODERM SOURCES 审中-公开
标题翻译：药物组合物和使用各种来源的FUCANS抑制纤维粘连或炎症疾病的方法
公开(公告)号：WO2006032144A1
公开(公告)日：2006-03-30
申请号：PCT/CA2005/001447
申请日：2005-09-23
申请人： ARC PHARMACEUTICALS, INC. , CASHMAN, Johanne , SPRINGATE, Christopher , WINTERNITZ, Charles
发明人： CASHMAN, Johanne , SPRINGATE, Christopher , WINTERNITZ, Charles
IPC分类号： A61K31/737 , A61K31/711 , A61K31/436 , A61K9/70 , A61K47/36 , A61P29/00 , A61P41/00
CPC分类号： A61K31/737 , A61K31/436 , A61K31/711 , A61L31/042 , C08L5/00 , Y10T307/675
摘要： Compositions and methods for the treatment, prevention, inhibition, etc, of inflammatory disease or fibrous adhesions involving administration of fucans from various echinoderm sources, alone or in combination with other agents useful for the treatment, prevention, inhibition, etc, of fibrous adhesions or inflammatory disease. The anti-fibrous adhesion agents provide significant therapeutic effect against fibrous adhesions while typically also providing low side effects. Further, since avariety of different anti-fibrous adhesion agents are discussed, various combinations of the agents can be selected as desired to reduce side effects in patients potentially suffering from other diseases or conditions and/or to provide other beneficial healthful or therapeutic effects, such as compositions that both inhibit fibrous adhesions and also treat cancer or arthritis or swelling or any of the variety of other diseases or conditions that can also be treated by one or more of the anti-fibrous adhesion agents herein. The compositions herein are also useful for the treatment of fibrous growths and conditions such as keloid trait that share similar biology with fibrous adhesions.
摘要翻译：用于治疗，预防，抑制炎症性疾病或纤维性粘连的组合物和方法，其包括从各种棘皮类动物来源单独或与其它可用于纤维粘连的治疗，预防，抑制等的试剂组合施用，炎性疾病。抗纤维粘附剂对纤维粘连提供显着的治疗作用，同时通常也提供低的副作用。此外，由于讨论了各种不同的抗纤维粘附剂，所以可以根据需要选择各种药剂的组合，以减少可能患有其它疾病或病症的患者的副作用和/或提供其他有益的健康或治疗效果，例如作为既可以抑制纤维粘连也可治疗癌症或关节炎或肿胀的组合物，也可以通过本文中一种或多种抗纤维粘附剂进行治疗的各种其他疾病或病症。本文的组合物也可用于治疗纤维生长和条件，例如与纤维粘连共享相似生物学的瘢痕疙瘩性状。

86. 发明申请

WO2006013003A1 UTILISATION DE PRODUITS DÉRIVÉS DE LA SÉLÉNOPROTÉINE T, DANS DES APPLICATIONS LIÉES À L'HOMÉOSTASIE CALCIQUE. 审中-公开
标题翻译：使用产自SELENOPROTEIN T的产品，与其相关的应用
公开(公告)号：WO2006013003A1
公开(公告)日：2006-02-09
申请号：PCT/EP2005/007903
申请日：2005-06-30
申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , ANOUAR, Youssef , GRUMOLATO, Luca , GALAS, Ludovic , GHZILI, Hafida , VAUDRY, Hubert
发明人： ANOUAR, Youssef , GRUMOLATO, Luca , GALAS, Ludovic , GHZILI, Hafida , VAUDRY, Hubert
IPC分类号： A61K38/16 , A61K31/711 , C12N15/63 , A01K67/027 , C12Q1/00 , A61P35/00
CPC分类号： A61K38/1709 , A61K31/711 , C07K14/4702
摘要： La présente invention est fondée sur la caractéristation de la sélénoprotéine T (SelT) comme étant impliquée dans la régulation du calcium intracellulaire. Elle porte donc sur des compositions comportant SelT ou un polynucléotide capable d'entraîner, dans une cellule hôte, l'expression de SelT ou l'inhibition de son expression. L'invention porte en particulier sur des compositions pharmaceutiques destinées à lutter contre des maladies liées à un défaut de l'homéostasie calcique.
摘要翻译：本发明基于硒蛋白T（SelT）参与细胞内钙调节的表征。因此，本发明涉及包含SelT或能够在宿主细胞中表达或抑制SelT表达的多核苷酸的组合物。特别地，本发明涉及用于治疗与钙稳态缺陷有关的疾病的药物组合物。

87. 发明申请

WO2005094899A8 CLUSTERIN ANTISENSE THERAPY FOR TREATMENT OF CANCER 审中-公开
标题翻译：用于治疗癌症的CLUSTERIN抗体治疗
公开(公告)号：WO2005094899A8
公开(公告)日：2006-02-02
申请号：PCT/CA2005000531
申请日：2005-04-04
申请人： UNIV BRITISH COLUMBIA , GLEAVE MARTIN E , CORMACK SCOTT D
发明人： GLEAVE MARTIN E , CORMACK SCOTT D
IPC分类号： A61K31/7088 , A61K31/711 , A61K48/00 , A61P35/00 , C12N15/11 , C12N15/113
CPC分类号： C12N15/1137 , A61K31/337 , A61K31/7052 , A61K31/7068 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K33/24 , A61N5/10 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2320/31 , C12N2310/3525
摘要： A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.
摘要翻译：提供了减少簇蛋白表达以提供治疗癌症方面的治疗益处的反义治疗方法，包括向需要治疗表达聚集蛋白的癌症的患者给予40至640mg抗聚集蛋白反义寡核苷酸。该方法可以包括施用化学治疗剂或药剂，放射疗法和/或激素消融治疗。本发明还包括配制成提供40至640mg的剂量的药物组合物，以及在配制药物中使用反义物。

88. 发明申请

WO2005001040A3 NON-LETHAL CONDITIONING METHODS FOR CONDITIONING A RECIPIENT FOR BONE MARROW TRANSPLANTATION 审中-公开
标题翻译：用于骨髓移植受体调节的非牙齿调节方法
公开(公告)号：WO2005001040A3
公开(公告)日：2005-04-14
申请号：PCT/US2004017051
申请日：2004-05-28
申请人： UNIV OF LOUISVILLE RES FOUNDAT , ILDSTAD SUZANNE T
发明人： ILDSTAD SUZANNE T
IPC分类号： A61K31/711 , A61K39/395 , C12N20060101
CPC分类号： A61K31/675 , A61K2039/505 , A61K2039/507 , C07K16/2809 , C07K16/2815
摘要： Mixed chimerism induces donor-specific transplantation tolerance to organ allografts. In this invention, recipient B10 (h2 ) mice were pretreated in vivo with anti-abeta-TCR and anit-CD8 mABs 3 days before total body irradiation (TBI) and transplanted with 15 X 10 allogenic (B10.BR; H2k) marrow cells. Engraftment occurred in 20%, 75% and 94% of animals conditioned with 100, 200 or 300 cGy TBI one month post bone marrow transplant (BMT), respectively. Animals without donor T cells lost their chimerism gradually within 6 months and rejected both donor and third-party skin grafts. In animals with donor T cell production, chimerism remained stable for >= 6 months and donor skin grafts were accepted. In the animals without donor T cell production, none of the expected stages of T cell development were present in the thymus, while in those with donor T cell production they were. Moreover, clonal deletion of Vbeta 5.1/2 and Vbeta 11 CD8 and CD4 T cells occurred only in chimeras with donor T cell production. These results show for the first time that donor T cell production plays a critical role in the maintenance of durable chimerism and induction of trnaplantation tolerance and is directly correlated with deletion of potentially autoreactive cells.
摘要翻译：混合嵌合体诱导供体特异性移植对器官同种异体移植的耐受性。在本发明中，在全身照射（TBI）前3天，用抗-Teta-TCR和anit-CD8mABs在体内预处理受体B10（h2b）小鼠，并用15×10 6同种异体移植（B10）。 BR; H2k）骨髓细胞。在骨髓移植（BMT）一个月后分别在100,200或300cGy TBI条件下进行移植的20％，75％和94％的移植物。没有供体T细胞的动物在6个月内逐渐失去嵌合体，并拒绝供体和第三方皮肤移植物。在具有供体T细胞产生的动物中，嵌合体保持稳定> = 6个月，并且接受供体皮肤移植物。在没有供体T细胞生产的动物中，T细胞发育的预期阶段都不存在于胸腺中，而在具有供体T细胞生产的那些中。此外，Vbeta 5.1 / 2 +和Vbeta 11 + CD8和CD4T细胞的克隆缺失仅在具有供体T细胞产生的嵌合体中发生。这些结果首次表明，供体T细胞的产生在维持持久的嵌合体和诱导trnaplantation耐受中起关键作用，并与潜在的自身反应性细胞的缺失直接相关。

89. 发明申请

WO2004050858A3 COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS 审中-公开
标题翻译：组成物，裂解物变体和与结肠特异性基因和蛋白质有关的方法
公开(公告)号：WO2004050858A3
公开(公告)日：2004-11-18
申请号：PCT/US0338808
申请日：2003-12-04
申请人： DIADEXUS INC , MACINA ROBERTO A , TURNER LEAH R , SUN YONGMING , RODRIGUEZ MARIA , BURCHAM TIMOTHY S
发明人： MACINA ROBERTO A , TURNER LEAH R , SUN YONGMING , RODRIGUEZ MARIA , BURCHAM TIMOTHY S
IPC分类号： C07K14/47 , C12N15/12 , C12Q1/68 , A61K31/7088 , A61K31/711 , C12N15/00 , C12N15/11 , C12P21/02
CPC分类号： C12Q1/6886 , A61K39/00 , C07K14/47 , C12Q2600/112
摘要： The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic colon cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating colon cancer and non-cancerous disease states in colon, identifying colon tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered colon tissue for treatment and research.
摘要翻译：本发明涉及存在于正常和瘤形成性结肠细胞中的新鉴定的核酸分子和多肽，包括核酸和多肽的片段，变体和衍生物。本发明还涉及本发明多肽的抗体以及本发明多肽的激动剂和拮抗剂。本发明还涉及含有本发明的核酸分子，多肽，抗体，激动剂和拮抗剂的组合物和使用这些组合物的方法。这些用途包括鉴定，诊断，监测，分期，成像和治疗结肠癌和非癌性疾病状态，鉴定结肠组织，监测和鉴定和/或设计本发明多肽的激动剂和拮抗剂。这些用途还包括基因治疗，转基因动物和细胞的生产以及用于治疗和研究的工程化结肠组织的生产。

90. 发明申请

WO2004020582A3 MAMMALIAN GENES INVOLVED IN RAPAMYCIN RESISTANCE AND TUMORGENESIS: RAPR6 GENES 审中-公开
标题翻译：涉及雷帕霉素抗性和致瘤性的哺乳动物基因：RAPR6基因
公开(公告)号：WO2004020582A3
公开(公告)日：2004-11-11
申请号：PCT/US0326075
申请日：2003-08-15
申请人： FUNCTIONAL GENETICS INC , LI LIMIN , AGHDASI BAHMAN
发明人： LI LIMIN , AGHDASI BAHMAN
IPC分类号： A61K38/00 , C07K14/47 , A61K31/711 , A61K38/16 , C07H21/04 , C07K14/435 , C07K16/18 , C12N15/85 , C12P21/00 , C12Q1/68
CPC分类号： C12Q1/6886 , A61K38/00 , C07K14/47 , C12Q2600/136 , C12Q2600/158
摘要： The invention provides nucleotide sequence of a novel mammalian gene, the RapR6 gene, which is involved in resistance and tumorgenesis, and amino acid sequences of the encoded proteins. The present invention also provides methods and compositions for regulating rapamycin resistance and/or tumorgenesis by modulating the expression and /or the activity of RapR6 gene. The invention also provides methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression and/or activity of RapR6 gene. The invention also provides methods and compositions for diagnosing and screening RapR6 mediated rapamycin resistance and/or tumorgenesis in patients. The invention further provides host cells a portion of whose RapR6 gene can be reversibly expressed, and to methods of using the RapR6 gene in evaluation and screening for drugs which regulate rapamycin resistance and/or tumorgenesis.
摘要翻译：本发明提供了新型哺乳动物基因的核苷酸序列，涉及抗性和肿瘤发生的RapR6基因，以及编码蛋白质的氨基酸序列。本发明还提供了通过调节RapR6基因的表达和/或活性来调节雷帕霉素抗性和/或肿瘤发生的方法和组合物。本发明还提供了通过调节RapR6基因的表达和/或活性来治疗疾病例如癌症的方法和组合物。本发明还提供了用于诊断和筛选患者中RapR6介导的雷帕霉素抗性和/或肿瘤发生的方法和组合物。本发明进一步提供其RapR6基因可被可逆表达的部分宿主细胞，以及使用RapR6基因评估和筛选调节雷帕霉素抗性和/或肿瘤发生的药物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式